Suppr超能文献

乳腺癌与避孕药——皇家全科医师学院口服避孕药研究的进一步报告

Breast cancer and the pill--a further report from the Royal College of General Practitioners' oral contraception study.

作者信息

Kay C R, Hannaford P C

机构信息

RCGP Manchester Research Unit, UK.

出版信息

Br J Cancer. 1988 Nov;58(5):675-80. doi: 10.1038/bjc.1988.285.

Abstract

An analysis of the occurrence of breast cancer in this long-term prospective cohort study shows a significant relative risk (RR) in women who have ever used oral contraceptives (OC) of 3.33 in women age 30 to 34 years at diagnosis and an RR of 5.88 (P = 0.0011) in women who were parity 1 at the time of diagnosis. In women below the age of 35 years the RR of 2.38 was not significant. There was no increased risk in women over the age of 35 years. A significant trend relating to duration of use was demonstrable in women who were parity 1 in the analysis of both current and ever-users. An analysis by time since stopping OC use revealed a significant trend in all ever-users, but the trends were much steeper in women of parity 1 or aged 30 to 34 years at diagnosis. There was no evidence that the increased rates in OC users were related to the oestrogen or progestogen dose. The 5 year survival rate in users diagnosed under the age of 35 years was significantly poorer than in comparable non-users. It is possible that the increased rates in younger OC users might be due to an accelerated presentation of breast cancer in those women who would otherwise have been diagnosed at a later time. The non-significant excess risk in users under 35 years of age was approximately 1 in 7,000 users per year. The unresolved discrepancies between the results of the published studies make it impossible at the present time to decide whether or not OC use is associated with an increased risk of breast cancer.

摘要

在这项长期前瞻性队列研究中,对乳腺癌发病情况的分析显示,诊断时年龄在30至34岁且曾使用口服避孕药(OC)的女性,其相对风险(RR)显著为3.33;诊断时为初产妇的女性,RR为5.88(P = 0.0011)。35岁以下女性的RR为2.38,不具有显著性。35岁以上女性没有增加的风险。在对现使用者和曾使用者的分析中,对于初产妇,使用时间与风险之间存在显著趋势。按停止使用OC后的时间进行分析显示,所有曾使用者都有显著趋势,但在诊断时为初产妇或年龄在30至34岁的女性中,趋势更为明显。没有证据表明OC使用者中发病率的增加与雌激素或孕激素剂量有关。35岁以下被诊断出的使用者的5年生存率显著低于可比的未使用者。年轻OC使用者发病率增加可能是由于那些原本会在更晚时候被诊断出乳腺癌的女性中,乳腺癌的发病加速。35岁以下使用者中不显著的额外风险约为每年每7000名使用者中有1例。已发表研究结果之间未解决的差异使得目前无法确定使用OC是否与乳腺癌风险增加有关。

相似文献

5
Oral contraceptives and breast cancer.口服避孕药与乳腺癌
Int J Epidemiol. 1982 Dec;11(4):316-22. doi: 10.1093/ije/11.4.316.

引用本文的文献

1
[Hormonal contraception and breast cancer risk].[激素避孕与乳腺癌风险]
Wien Med Wochenschr. 2010 Nov;160(19-20):483-6. doi: 10.1007/s10354-010-0807-0. Epub 2010 Aug 16.
5
Oral contraceptives and cancer. A review of the evidence.口服避孕药与癌症。证据综述。
Drug Saf. 1996 Apr;14(4):260-72. doi: 10.2165/00002018-199614040-00006.

本文引用的文献

2
Breast cancer in relation to patterns of oral contraceptive use.与口服避孕药使用模式相关的乳腺癌
Am J Epidemiol. 1982 Oct;116(4):643-51. doi: 10.1093/oxfordjournals.aje.a113447.
3
Breast cancer and oral contraceptive use.乳腺癌与口服避孕药的使用。
Am J Epidemiol. 1984 Feb;119(2):167-76. doi: 10.1093/oxfordjournals.aje.a113735.
8
Oral contraceptives and breast cancer: a national study.口服避孕药与乳腺癌:一项全国性研究。
Br Med J (Clin Res Ed). 1986 Sep 20;293(6549):723-6. doi: 10.1136/bmj.293.6549.723.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验